Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View
Abstract
1. Influenza—Introduction
2. Vaccination Strategies and Currently Licenced Vaccines
3. To Mimic the Natural Immune Response to Influenza—The Goal of Future Vaccines?
4. Adjuvants
5. Safety
6. Challenge: Lack of Knowledge due to Clinical Underdiagnosis of Influenza
7. Our Perspective for the Expectations for Future Influenza Vaccines
8. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Potter, C.W. A history of influenza. J. Appl. Microbiol. 2001, 91, 572–579. [Google Scholar] [CrossRef] [PubMed]
- Iuliano, A.D.; Roguski, K.M.; Chang, H.H.; Muscatello, D.J.; Palekar, R.; Tempia, S.; Cohen, C.; Gran, J.M.; Schanzer, D.; Cowling, B.J.; et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018, 391, 1285–1300. [Google Scholar] [CrossRef]
- Meltzer, M.I.; Cox, N.J.; Fukuda, K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg. Infect. Dis. 1999, 5, 659–671. [Google Scholar] [CrossRef] [PubMed]
- Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.; Bridges, C.B. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007, 25, 5086–5096. [Google Scholar] [CrossRef] [PubMed]
- Rothman, T. The cost of influenza disease burden in U.S. Population. Int. J. Econ. Manag. Sci. 2017, 6, 443. [Google Scholar] [CrossRef]
- Wooten, K.G.; Wortley, P.M.; Singleton, J.A.; Euler, G.L. Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and hispanic americans. Vaccine 2012, 30, 6927–6934. [Google Scholar] [CrossRef] [PubMed]
- Cheney, M.K.; John, R. Underutilization of influenza vaccine:A test of the health belief model. SAGE Open 2013, 3. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). People at High Risk of Developing Flu–Related Complications. Available online: https://www.cdc.gov/flu/about/disease/high_risk.htm (accessed on 28 April 2018).
- CDC. Vaccination: Who Should Do It, Who Should Not and Who Should Take Precautions. Available online: https://www.cdc.gov/flu/protect/whoshouldvax.htm (accessed on 20 April 2018).
- Hodgson, D.; Baguelin, M.; van Leeuwen, E.; Panovska-Griffiths, J.; Ramsay, M.; Pebody, R.; Atkins, K.E. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in england and wales: A modelling and cost-effectiveness analysis. Lancet Public Health 2017, 2, e74–e81. [Google Scholar] [CrossRef]
- Heikkinen, T. Influenza in children. Acta Paediatr. 2006, 95, 778–784. [Google Scholar] [CrossRef] [PubMed]
- De Jong, J.C.; Beyer, W.E.; Palache, A.M.; Rimmelzwaan, G.F.; Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 2000, 61, 94–99. [Google Scholar] [CrossRef]
- Xie, H.; Wan, X.F.; Ye, Z.; Plant, E.P.; Zhao, Y.; Xu, Y.; Li, X.; Finch, C.; Zhao, N.; Kawano, T.; et al. H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci. Rep. 2015, 5, 15279. [Google Scholar] [CrossRef] [PubMed]
- Skowronski, D.M.; Chambers, C.; De Serres, G.; Dickinson, J.A.; Winter, A.-L.; Hickman, R.; Chan, T.; Jassem, A.N.; Drews, S.J.; Charest, H.; et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): Interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Eurosurveillance 2018, 23. [Google Scholar] [CrossRef] [PubMed]
- Castilla, J.; Navascués, A.; Casado, I.; Pérez-García, A.; Aguinaga, A.; Ezpeleta, G.; Pozo, F.; Ezpeleta, C.; Martínez-Baz, I.; Network, P.H.C.S.; et al. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza b, northern spain, 2017/18. Eurosurveillance 2018, 23. [Google Scholar] [CrossRef] [PubMed]
- Perdue, M.L.; Arnold, F.; Li, S.; Donabedian, A.; Cioce, V.; Warf, T.; Huebner, R. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 2011, 10, 1183–1194. [Google Scholar] [CrossRef] [PubMed]
- Tripp, R.A.; Tompkins, S.M. Virus-vectored influenza virus vaccines. Viruses 2014, 6, 3055–3079. [Google Scholar] [CrossRef] [PubMed]
- Kon, T.C.; Onu, A.; Berbecila, L.; Lupulescu, E.; Ghiorgisor, A.; Kersten, G.F.; Cui, Y.-Q.; Amorij, J.-P.; Van der Pol, L. Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE 2016, 11, e0150700. [Google Scholar] [CrossRef] [PubMed]
- Wong, S.S.; Webby, R.J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476–492. [Google Scholar] [CrossRef] [PubMed]
- Wilkinson, K.; Wei, Y.; Szwajcer, A.; Rabbani, R.; Zarychanski, R.; Abou-Setta, A.M.; Mahmud, S.M. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine 2017, 35, 2775–2780. [Google Scholar] [CrossRef] [PubMed]
- Young-Xu, Y.; Van Aalst, R.; Mahmud, S.M.; Rothman, K.J.; Thornton Snider, J.; Westreich, D.; Mor, V.; Gravenstein, S.; Lee, J.K.H.; Thommes, E.W.; et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients. J. Infect. Dis. 2018, 217, 1718–1727. [Google Scholar] [CrossRef] [PubMed]
- Woolthuis, R.G.; Wallinga, J.; van Boven, M. Variation in loss of immunity shapes influenza epidemics and the impact of vaccination. BMC Infect. Dis. 2017, 17, 632. [Google Scholar] [CrossRef] [PubMed]
- Carter, N.J.; Curran, M.P. Live attenuated influenza vaccine (Flumist; Fluenz): A review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71, 1591–1622. [Google Scholar] [CrossRef] [PubMed]
- Ambrose, C.S.; Luke, C.; Coelingh, K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir. Viruses 2008, 2, 193–202. [Google Scholar] [CrossRef] [PubMed]
- Cha, T.-A.; Kao, K.; Zhao, J.; Fast, P.E.; Mendelman, P.M.; Arvin, A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 2000, 38, 839–845. [Google Scholar] [PubMed]
- Cox, M.M.; Patriarca, P.A.; Treanor, J. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir. Viruses 2008, 2, 211–219. [Google Scholar] [CrossRef] [PubMed]
- Cox, M.M.; Izikson, R.; Post, P.; Dunkle, L. Safety, efficacy, and immunogenicity of flublok in the prevention of seasonal influenza in adults. Ther. Adv. Vaccines 2015, 3, 97–108. [Google Scholar] [CrossRef] [PubMed]
- Cox, R.J. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccines Immunother. 2013, 9, 405–408. [Google Scholar] [CrossRef]
- Andrewes, C.H.; Laidlaw, P.P.; Smith, W. Influenza: Observations on the recovery of virus from man and on the antibody content of human sera. Br. J. Exp. Pathol. 1935, 16, 566–582. [Google Scholar] [CrossRef]
- Clements, M.L.; Murphy, B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 1986, 23, 66–72. [Google Scholar] [PubMed]
- Hobson, D.; Curry, R.L.; Beare, A.S.; Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 1972, 70, 767–777. [Google Scholar] [CrossRef] [PubMed]
- Jefferson, T.; Di Pietrantonj, C.; Rivetti, A.; Bawazeer, G.A.; Al-Ansary, L.A.; Ferroni, E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2010, Cd001269. [Google Scholar] [CrossRef]
- Surveillance of Influenza and Other Respiratory Infections in the Netherlands: Winter 2014/2015. Available online: https://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2015/oktober/Surveillance_of_influenza_and_other_respiratory_infections_in_the_Netherlands_winter_2014_2015 (accessed on 20 April 2018).
- Pebody, R.G.; Warburton, F.; Ellis, J.; Andrews, N.; Thompson, C.; von Wissmann, B.; Green, H.K.; Cottrell, S.; Johnston, J.; de Lusignan, S.; et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Eurosurveillance 2015, 20, 21025. [Google Scholar] [CrossRef] [PubMed]
- Tisa, V.; Barberis, I.; Faccio, V.; Paganino, C.; Trucchi, C.; Martini, M.; Ansaldi, F. Quadrivalent influenza vaccine: A new opportunity to reduce the influenza burden. J. Prev. Med. Hyg. 2016, 57, E28–E33. [Google Scholar] [PubMed]
- European Centre for Disease Prevention and Control (ECDC). Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. Eurosurveillance 2018, 23, 18-00146. [Google Scholar]
- Hoft, D.F.; Babusis, E.; Worku, S.; Spencer, C.T.; Lottenbach, K.; Truscott, S.M.; Abate, G.; Sakala, I.G.; Edwards, K.M.; Creech, C.B.; et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse t-cell responses in young children. J. Infect. Dis. 2011, 204, 845–853. [Google Scholar] [CrossRef] [PubMed]
- He, X.S.; Holmes, T.H.; Zhang, C.; Mahmood, K.; Kemble, G.W.; Lewis, D.B.; Dekker, C.L.; Greenberg, H.B.; Arvin, A.M. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 2006, 80, 11756–11766. [Google Scholar] [CrossRef] [PubMed]
- Forrest, B.D.; Pride, M.W.; Dunning, A.J.; Capeding, M.R.; Chotpitayasunondh, T.; Tam, J.S.; Rappaport, R.; Eldridge, J.H.; Gruber, W.C. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 2008, 15, 1042–1053. [Google Scholar] [CrossRef] [PubMed]
- Ambrose, C.S.; Wu, X.; Jones, T.; Mallory, R.M. The role of nasal iga in children vaccinated with live attenuated influenza vaccine. Vaccine 2012, 30, 6794–6801. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.; Brokstad, K.A.; Pathirana, R.D.; Bredholt, G.; Jul-Larsen, A.; Trieu, M.C.; Lartey, S.L.; Montemoli, E.; Tondel, C.; Aarstad, H.J.; et al. Live attenuated influenza vaccine in children induces B-cell responses in tonsils. J. Infect. Dis. 2016, 214, 722–731. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.I.; Zhou, F.; Brokstad, K.A.; Sridhar, S.; Cox, R.J. Boosting of cross-reactive and protection-associated t cells in children after live attenuated influenza vaccination. J. Infect. Dis. 2017, 215, 1527–1535. [Google Scholar] [CrossRef] [PubMed]
- Jefferson, T.O.; Rivetti, D.; Di Pietrantonj, C.; Rivetti, A.; Demicheli, V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2007, Cd001269. [Google Scholar] [CrossRef]
- Jefferson, T.; Rivetti, A.; Harnden, A.; Di Pietrantonj, C.; Demicheli, V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2008, Cd004879. [Google Scholar] [CrossRef]
- Hayward, A.C.; Wang, L.; Goonetilleke, N.; Fragaszy, E.B.; Bermingham, A.; Copas, A.; Dukes, O.; Millett, E.R.; Nazareth, I.; Nguyen-Van-Tam, J.S.; et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 2015, 191, 1422–1431. [Google Scholar] [CrossRef] [PubMed]
- Pebody, R.G.; Green, H.K.; Andrews, N.; Zhao, H.; Boddington, N.; Bawa, Z.; Durnall, H.; Singh, N.; Sunderland, A.; Letley, L.; et al. Uptake and impact of a new live attenuated influenza vaccine programme in england: Early results of a pilot in primary school-age children, 2013/14 influenza season. Eurosurveillance 2014, 19, 20823. [Google Scholar] [CrossRef] [PubMed]
- Glezen, W.P. Universal influenza vaccination and live attenuated influenza vaccination of children. Pediatr. Infect. Dis. J. 2008, 27, S104–S109. [Google Scholar] [CrossRef] [PubMed]
- ACIP Votes Down Use of LAIV for 2016–2017 Flu Season. Available online: https://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html (accessed on 18 April 2018).
- Advisory Committee on Immunization Practices (ACIP) Recommends a Preference for Using the Nasal Spray Flu Vaccine. Available online: https://www.cdc.gov/media/releases/2014/s0625-acip.html (accessed on 18 April 2018).
- Nohynek, H.; Baum, U.; Syrjanen, R.; Ikonen, N.; Sundman, J.; Jokinen, J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds—A nationwide cohort study finland, influenza season 2015/16. Eurosurveillance 2016, 21, 30346. [Google Scholar] [CrossRef] [PubMed]
- Pebody, R.; Warburton, F.; Ellis, J.; Andrews, N.; Potts, A.; Cottrell, S.; Johnston, J.; Reynolds, A.; Gunson, R.; Thompson, C.; et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Eurosurveillance 2016, 21, 30348. [Google Scholar] [CrossRef] [PubMed]
- Zimmerman, R.K.; Nowalk, M.P.; Chung, J.; Jackson, M.L.; Jackson, L.A.; Petrie, J.G.; Monto, A.S.; McLean, H.Q.; Belongia, E.A.; Gaglani, M.; et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin. Infect. Dis. 2016, 63, 1564–1573. [Google Scholar] [CrossRef] [PubMed]
- Victor, J.C.; Lewis, K.D.C.; Diallo, A.; Niang, M.N.; Diarra, B.; Dia, N.; Ortiz, J.R.; Widdowson, M.-A.; Feser, J.; Hoagland, R.; et al. Efficacy of a russian-backbone live attenuated influenza vaccine among children in senegal: A randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 2016, 4, e955–e965. [Google Scholar] [CrossRef]
- Brooks, W.A.; Zaman, K.; Lewis, K.D.C.; Ortiz, J.R.; Goswami, D.; Feser, J.; Sharmeen, A.T.; Nahar, K.; Rahman, M.; Rahman, M.Z.; et al. Efficacy of a russian-backbone live attenuated influenza vaccine among young children in Bangladesh: A randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 2016, 4, e946–e954. [Google Scholar] [CrossRef]
- Pebody, R.; Sile, B.; Warburton, F.; Sinnathamby, M.; Tsang, C.; Zhao, H.; Ellis, J.; Andrews, N. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Eurosurveillance 2017, 22, 30450. [Google Scholar] [CrossRef] [PubMed]
- Chung, J.R.; Flannery, B.; Thompson, M.G.; Gaglani, M.; Jackson, M.L.; Monto, A.S.; Nowalk, M.P.; Talbot, H.K.; Treanor, J.J.; Belongia, E.A.; et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016, 137, e20153279. [Google Scholar] [CrossRef] [PubMed]
- ECDC. Seasonal Influenza Vaccines. Available online: https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet (accessed on 18th April 2018).
- Waffarn, E.E.; Baumgarth, N. Protective B cell responses to flu—No fluke! J. Immunol. 2011, 186, 3823–3829. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, S.; Jaimes, M.C.; Holmes, T.H.; Dekker, C.L.; Mahmood, K.; Kemble, G.W.; Arvin, A.M.; Greenberg, H.B. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 2007, 81, 215–228. [Google Scholar] [CrossRef] [PubMed]
- Huang, K.Y.; Li, C.K.; Clutterbuck, E.; Chui, C.; Wilkinson, T.; Gilbert, A.; Oxford, J.; Lambkin-Williams, R.; Lin, T.Y.; McMichael, A.J.; et al. Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model. J. Infect. Dis. 2014, 209, 1354–1361. [Google Scholar] [CrossRef] [PubMed]
- Powers, D.C.; Smith, G.E.; Anderson, E.L.; Kennedy, D.J.; Hackett, C.S.; Wilkinson, B.E.; Volvovitz, F.; Belshe, R.B.; Treanor, J.J. Influenza a virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis. 1995, 171, 1595–1599. [Google Scholar] [CrossRef] [PubMed]
- Krammer, F.; Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 2015, 14, 167–182. [Google Scholar] [CrossRef] [PubMed]
- Carter, D.M.; Darby, C.A.; Lefoley, B.C.; Crevar, C.J.; Alefantis, T.; Oomen, R.; Anderson, S.F.; Strugnell, T.; Cortes-Garcia, G.; Vogel, T.U.; et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J. Virol. 2016, 90, 4720–4734. [Google Scholar] [CrossRef] [PubMed]
- Carter, D.M.; Darby, C.A.; Johnson, S.K.; Carlock, M.A.; Kirchenbaum, G.A.; Allen, J.D.; Vogel, T.U.; Delagrave, S.; DiNapoli, J.; Kleanthous, H.; et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J. Virol. 2017, 91, e01283. [Google Scholar] [CrossRef] [PubMed]
- Wong, T.M.; Allen, J.D.; Bebin-Blackwell, A.G.; Carter, D.M.; Alefantis, T.; DiNapoli, J.; Kleanthous, H.; Ross, T.M. Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J. Virol. 2017, 91, e01581. [Google Scholar] [CrossRef] [PubMed]
- Nachbagauer, R.; Kinzler, D.; Choi, A.; Hirsh, A.; Beaulieu, E.; Lecrenier, N.; Innis, B.L.; Palese, P.; Mallett, C.P.; Krammer, F. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines 2016, 1, 16015. [Google Scholar] [CrossRef] [PubMed]
- Impagliazzo, A.; Milder, F.; Kuipers, H.; Wagner, M.V.; Zhu, X.; Hoffman, R.M.; van Meersbergen, R.; Huizingh, J.; Wanningen, P.; Verspuij, J.; et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015, 349, 1301–1306. [Google Scholar] [CrossRef] [PubMed]
- Yassine, H.M.; Boyington, J.C.; McTamney, P.M.; Wei, C.J.; Kanekiyo, M.; Kong, W.P.; Gallagher, J.R.; Wang, L.; Zhang, Y.; Joyce, M.G.; et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 2015, 21, 1065–1070. [Google Scholar] [CrossRef] [PubMed]
- Valkenburg, S.A.; Mallajosyula, V.V.; Li, O.T.; Chin, A.W.; Carnell, G.; Temperton, N.; Varadarajan, R.; Poon, L.L. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep. 2016, 6, 22666. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Begom, S.; Bermingham, A.; Hoschler, K.; Adamson, W.; Carman, W.; Bean, T.; Barclay, W.; Deeks, J.J.; Lalvani, A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 2013, 19, 1305–1312. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Brokstad, K.A.; Cox, R.J. Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines. Vaccines 2015, 3, 373–389. [Google Scholar] [CrossRef] [PubMed]
- He, X.S.; Holmes, T.H.; Mahmood, K.; Kemble, G.W.; Dekker, C.L.; Arvin, A.M.; Greenberg, H.B. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J. Infect. Dis. 2008, 197, 803–811. [Google Scholar] [CrossRef] [PubMed]
- Chiu, C.; Openshaw, P.J. Antiviral b cell and T cell immunity in the lungs. Nat. Immunol. 2015, 16, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Begom, S.; Bermingham, A.; Ziegler, T.; Roberts, K.L.; Barclay, W.S.; Openshaw, P.; Lalvani, A. Predominance of heterosubtypic ifn-gamma-only-secreting effector memory t cells in pandemic H1N1 naive adults. Eur. J. Immunol. 2012, 42, 2913–2924. [Google Scholar] [CrossRef] [PubMed]
- Bonduelle, O.; Carrat, F.; Luyt, C.E.; Leport, C.; Mosnier, A.; Benhabiles, N.; Krivine, A.; Rozenberg, F.; Yahia, N.; Samri, A.; et al. Characterization of pandemic influenza immune memory signature after vaccination or infection. J. Clin. Investig. 2014, 124, 3129–3136. [Google Scholar] [CrossRef] [PubMed]
- Abbas, A.K.; Lichtman, A.H.; Pillai, S. Cellular and Molecular Immunology, 9th ed.; Elsevier: New York, NY, USA, 2017. [Google Scholar]
- Lanzavecchia, A.; Sallusto, F. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 2005, 17, 326–332. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Wan, Y.; Qiu, C.; Quinones-Parra, S.; Zhu, Z.; Loh, L.; Tian, D.; Ren, Y.; Hu, Y.; Zhang, X.; et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat. Commun. 2015, 6, 6833. [Google Scholar] [CrossRef] [PubMed]
- Schulman, J.L.; Kilbourne, E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J. Bacteriol. 1965, 89, 170–174. [Google Scholar] [PubMed]
- Slepushkin, A.N. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull. World Health Organ. 1959, 20, 297–301. [Google Scholar] [PubMed]
- Biddison, W.E.; Shaw, S.; Nelson, D.L. Virus specificity of human influenza virus-immune cytotoxic T cells. J. Immunol. 1979, 122, 660–664. [Google Scholar] [PubMed]
- Lee, P.S.; Yoshida, R.; Ekiert, D.C.; Sakai, N.; Suzuki, Y.; Takada, A.; Wilson, I.A. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl. Acad. Sci. USA 2012, 109, 17040–17045. [Google Scholar] [CrossRef] [PubMed]
- Benjamin, E.; Wang, W.; McAuliffe, J.M.; Palmer-Hill, F.J.; Kallewaard, N.L.; Chen, Z.; Suzich, J.A.; Blair, W.S.; Jin, H.; Zhu, Q. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J. Virol. 2014, 88, 6743–6750. [Google Scholar] [CrossRef] [PubMed]
- Boonsathorn, N.; Panthong, S.; Koksunan, S.; Chittaganpitch, M.; Phuygun, S.; Waicharoen, S.; Prachasupap, A.; Sasaki, T.; Kubota-Koketsu, R.; Yasugi, M.; et al. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza a viruses. Biochem. Biophys. Res. Commun. 2014, 452, 865–870. [Google Scholar] [CrossRef] [PubMed]
- Yewdell, J.W.; Bennink, J.R.; Smith, G.L.; Moss, B. Influenza a virus nucleoprotein is a major target antigen for cross-reactive anti-influenza a virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1985, 82, 1785–1789. [Google Scholar] [CrossRef] [PubMed]
- Gotch, F.; McMichael, A.; Smith, G.; Moss, B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 1987, 165, 408–416. [Google Scholar] [CrossRef] [PubMed]
- Scheible, K.; Zhang, G.; Baer, J.; Azadniv, M.; Lambert, K.; Pryhuber, G.; Treanor, J.J.; Topham, D.J. CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 2011, 29, 2159–2168. [Google Scholar] [CrossRef] [PubMed]
- Jameson, J.; Cruz, J.; Ennis, F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72, 8682–8689. [Google Scholar] [PubMed]
- Agrati, C.; Castilletti, C.; Cimini, E.; Lapa, D.; Quartu, S.; Caglioti, C.; Lanini, S.; Cattoli, G.; Martini, F.; Ippolito, G.; et al. Cellular and humoral cross-immunity against two H3N2V influenza strains in presumably unexposed healthy and hiv-infected subjects. PLoS ONE 2014, 9, e105651. [Google Scholar] [CrossRef] [PubMed]
- Lee, L.Y.; Ha do, L.A.; Simmons, C.; de Jong, M.D.; Chau, N.V.; Schumacher, R.; Peng, Y.C.; McMichael, A.J.; Farrar, J.J.; Smith, G.L.; et al. Memory t cells established by seasonal human influenza a infection cross-react with avian influenza a (H5N1) in healthy individuals. J. Clin. Investig. 2008, 118, 3478–3490. [Google Scholar] [CrossRef] [PubMed]
- Quinones-Parra, S.; Grant, E.; Loh, L.; Nguyen, T.H.; Campbell, K.A.; Tong, S.Y.; Miller, A.; Doherty, P.C.; Vijaykrishna, D.; Rossjohn, J.; et al. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl. Acad. Sci. USA 2014, 111, 1049–1054. [Google Scholar] [CrossRef] [PubMed]
- Schotsaert, M.; Ysenbaert, T.; Smet, A.; Schepens, B.; Vanderschaeghe, D.; Stegalkina, S.; Vogel, T.U.; Callewaert, N.; Fiers, W.; Saelens, X. Long-lasting cross-protection against influenza A by neuraminidase and M2E-based immunization strategies. Sci. Rep. 2016, 6, 24402. [Google Scholar] [CrossRef] [PubMed]
- Antrobus, R.D.; Coughlan, L.; Berthoud, T.K.; Dicks, M.D.; Hill, A.V.; Lambe, T.; Gilbert, S.C. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther. 2014, 22, 668–674. [Google Scholar] [CrossRef] [PubMed]
- Berthoud, T.K.; Hamill, M.; Lillie, P.J.; Hwenda, L.; Collins, K.A.; Ewer, K.J.; Milicic, A.; Poyntz, H.C.; Lambe, T.; Fletcher, H.A.; et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011, 52, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Braucher, D.R.; Henningson, J.N.; Loving, C.L.; Vincent, A.L.; Kim, E.; Steitz, J.; Gambotto, A.A.; Kehrli, M.E., Jr. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clin. Vaccine Immunol. 2012, 19, 1722–1729. [Google Scholar] [CrossRef] [PubMed]
- Gomez, C.E.; Najera, J.L.; Krupa, M.; Perdiguero, B.; Esteban, M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 2011, 11, 189–217. [Google Scholar] [CrossRef] [PubMed]
- Antrobus, R.D.; Berthoud, T.K.; Mullarkey, C.E.; Hoschler, K.; Coughlan, L.; Zambon, M.; Hill, A.V.; Gilbert, S.C. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol. Ther. 2014, 22, 233–238. [Google Scholar] [CrossRef] [PubMed]
- Le Bon, A.; Schiavoni, G.; D’Agostino, G.; Gresser, I.; Belardelli, F.; Tough, D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14, 461–470. [Google Scholar] [CrossRef]
- Arakawa, T. Adjuvants: No longer a ‘dirty little secret’, but essential key players in vaccines of the future. Expert Rev. Vaccines 2011, 10, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Broadbent, A.J.; Subbarao, K. Influenza virus vaccines: Lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 2011, 1, 254–262. [Google Scholar] [CrossRef] [PubMed]
- Reed, S.G.; Orr, M.T.; Fox, C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013, 19, 1597–1608. [Google Scholar] [CrossRef] [PubMed]
- Di Pasquale, A.; Preiss, S.; Da Silva, F.T.; Garcon, N. Vaccine adjuvants: From 1920 to 2015 and beyond. Vaccines 2015, 3, 320–343. [Google Scholar] [CrossRef] [PubMed]
- Morel, S.; Didierlaurent, A.; Bourguignon, P.; Delhaye, S.; Baras, B.; Jacob, V.; Planty, C.; Elouahabi, A.; Harvengt, P.; Carlsen, H.; et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29, 2461–2473. [Google Scholar] [CrossRef] [PubMed]
- Vesikari, T.; Pepin, S.; Kusters, I.; Hoffenbach, A.; Denis, M. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum. Vaccines Immunother. 2012, 8, 1283–1292. [Google Scholar] [CrossRef] [PubMed]
- Galson, J.D.; Truck, J.; Kelly, D.F.; van der Most, R. Investigating the effect of AS03 adjuvant on the plasma cell repertoire following PH1N1 influenza vaccination. Sci. Rep. 2016, 6, 37229. [Google Scholar] [CrossRef] [PubMed]
- Domnich, A.; Arata, L.; Amicizia, D.; Puig-Barbera, J.; Gasparini, R.; Panatto, D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2017, 35, 513–520. [Google Scholar] [CrossRef] [PubMed]
- Ohmit, S.E.; Victor, J.C.; Rotthoff, J.R.; Teich, E.R.; Truscon, R.K.; Baum, L.L.; Rangarajan, B.; Newton, D.W.; Boulton, M.L.; Monto, A.S. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 2006, 355, 2513–2522. [Google Scholar] [CrossRef] [PubMed]
- Bridges, C.B.; Thompson, W.W.; Meltzer, M.I.; Reeve, G.R.; Talamonti, W.J.; Cox, N.J.; Lilac, H.A.; Hall, H.; Klimov, A.; Fukuda, K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000, 284, 1655–1663. [Google Scholar] [CrossRef] [PubMed]
- Nichol, K.L.; Lind, A.; Margolis, K.L.; Murdoch, M.; McFadden, R.; Hauge, M.; Magnan, S.; Drake, M. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 1995, 333, 889–893. [Google Scholar] [CrossRef] [PubMed]
- Lancet, T. Addressing decreasing vaccine coverage in the EU. Lancet 2018, 391, 1638. [Google Scholar] [CrossRef]
- King, C.; Leask, J. The impact of a vaccine scare on parental views, trust and information needs: A qualitative study in Sydney, Australia. BMC Public Health 2017, 17, 106. [Google Scholar] [CrossRef] [PubMed]
- Blyth, C.C.; Jacoby, P.; Effler, P.V.; Kelly, H.; Smith, D.W.; Robins, C.; Willis, G.A.; Levy, A.; Keil, A.D.; Richmond, P.C. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics 2014, 133, e1218. [Google Scholar] [CrossRef] [PubMed]
- Nohynek, H.; Jokinen, J.; Partinen, M.; Vaarala, O.; Kirjavainen, T.; Sundman, J.; Himanen, S.L.; Hublin, C.; Julkunen, I.; Olsen, P.; et al. AS03 adjuvanted ah1n1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7, e33536. [Google Scholar] [CrossRef] [PubMed]
- The MPA Investigates Reports of Narcolepsy in Patients Vaccinated with Pandemrix. Available online: https://lakemedelsverket.se/english/All-news/NYHETER-2010/The-MPA-investigates-reports-of-narcolepsy-in-patients-vaccinated-with-Pandemrix/2010 (accessed on 20 April 2018).
- Stowe, J.; Andrews, N.; Kosky, C.; Dennis, G.; Eriksson, S.; Hall, A.; Leschziner, G.; Reading, P.; Shneerson, J.M.; Donegan, K.; et al. Risk of narcolepsy after AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in adults: A case-coverage study in england. Sleep 2016, 39, 1051–1057. [Google Scholar] [CrossRef] [PubMed]
- O’Flanagan, D.; Barret, A.S.; Foley, M.; Cotter, S.; Bonner, C.; Crowe, C.; Lynch, B.; Sweeney, B.; Johnson, H.; McCoy, B.; et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009–December 2010. Eurosurveillance 2014, 19, 20789. [Google Scholar] [CrossRef] [PubMed]
- Partinen, M.; Saarenpää-Heikkilä, O.; Ilveskoski, I.; Hublin, C.; Linna, M.; Olsén, P.; Nokelainen, P.; Alén, R.; Wallden, T.; Espo, M.; et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012, 7, e33723. [Google Scholar] [CrossRef] [PubMed]
- Miller, E.; Andrews, N.; Stellitano, L.; Stowe, J.; Winstone, A.M.; Shneerson, J.; Verity, C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. Br. Med. J. 2013, 346, f794. [Google Scholar] [CrossRef] [PubMed]
- Duffy, J.; Weintraub, E.; Vellozzi, C.; DeStefano, F.; Vaccine Safety, D. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. Neurology 2014, 83, 1823–1830. [Google Scholar] [CrossRef] [PubMed]
- Jorgensen, P.; Mereckiene, J.; Cotter, S.; Johansen, K.; Tsolova, S.; Brown, C. How close are countries of the who european region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine 2018, 36, 442–452. [Google Scholar] [CrossRef] [PubMed]
- CDC. Rapid Influenza Diagnostic Tests. Available online: https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm (accessed on 20 April 2018).
- Krammer, F. The quest for a universal flu vaccine: Headless HA 2.0. Cell Host Microbe 2015, 18, 395–397. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.; Bredholt, G.; Brokstad, K.A.; Pathirana, R.D.; Aarstad, H.J.; Tondel, C.; Cox, R.J. Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J. Infect. Dis. 2015, 211, 1541–1549. [Google Scholar] [CrossRef] [PubMed]
- Ilyushina, N.A.; Haynes, B.C.; Hoen, A.G.; Khalenkov, A.M.; Housman, M.L.; Brown, E.P.; Ackerman, M.E.; Treanor, J.J.; Luke, C.J.; Subbarao, K.; et al. Live attenuated and inactivated influenza vaccines in children. J. Infect. Dis. 2015, 211, 352–360. [Google Scholar] [CrossRef] [PubMed]
- Fisman, D.N.; Bogoch, I.I. Have you herd? Indirect flu vaccine effects are critically important. Lancet Public Health 2017, 2, e57–e58. [Google Scholar] [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mohn, K.G.-I.; Zhou, F. Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines 2018, 6, 32. https://doi.org/10.3390/vaccines6020032
Mohn KG-I, Zhou F. Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines. 2018; 6(2):32. https://doi.org/10.3390/vaccines6020032
Chicago/Turabian StyleMohn, Kristin G.-I., and Fan Zhou. 2018. "Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View" Vaccines 6, no. 2: 32. https://doi.org/10.3390/vaccines6020032
APA StyleMohn, K. G.-I., & Zhou, F. (2018). Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines, 6(2), 32. https://doi.org/10.3390/vaccines6020032